Evidence map›Paper›PMID 33565332›Full record

ReviewPersonalized medicine2021

Stem cells as therapeutic targets in colorectal cancer.

Alicja Zalewski, Adam E Snook, Scott A Waldman

Abstract readReview
In one paragraph

Review in Personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. The Impact of Cancer Stem Cells in Colorectal Cancer.International journal of molecular sciences · 2024
    Review
  8. Article
  9. Cancers · 2024
    Article
  10. Review
  11. Cell Therapy as Target Therapy against Colon Cancer Stem Cells.International journal of molecular sciences · 2023
    Review
  12. Article
  13. The Role of Tumor Stem Cells in Colorectal Cancer Drug Resistance.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alicja ZalewskiDepartment of Surgery, Thomas Jefferson University Hospital, 1020 Locust St, JAH368, Philadelphia, PA 19107, USA.ORCID 0000-0003-2627-3798
Adam E SnookDepartment of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, 1020 Locust St, JAH368, Philadelphia, PA 19107, USA.ORCID 0000-0001-9216-4560
Scott A WaldmanDepartment of Surgery, Thomas Jefferson University Hospital, 1020 Locust St, JAH368, Philadelphia, PA 19107, USA.ORCID 0000-0001-6619-175X

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Andrew Chapman · 1995 to 2026
$94.8M
CLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM008562 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI WALTER K KRAFT, Scott A. Waldman · 1995 to 2026
$10.2M
Guanylin GUCY2C axis in Colorectal Cancer InitiationR01CA204481 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2017 to 2021
$1.8M
(PQ1) GUCY2C hormone loss translates APC-Beta-catenin mutations into epithelial transformationR01CA206026 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2016 to 2020
$1.8M
NCI NIH HHS CA204881, CA206026, CA56036NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA204481NCI NIH HHS R01 CA206026NIGMS NIH HHS T32 GM008562
6 · The paper itself

Abstract

Colorectal cancer continues to represent a significant burden on public health as the second highest cause of cancer mortality, when men and women are combined, in the US. About 50% of patients either present with late-stage metastatic disease, or develop metastatic recurrences, and ultimately die. In turn, this mortality largely reflects cancer stem cells, tumor-initiating cells that are responsible for cancer progression, drug resistance, recurrence and metastasis. This review summarizes the unique properties of colorectal cancer stem cells, and the emerging strategies by which they can be selectively targeted as a therapeutic approach to eradicating this disease.

Indexed as

AC133 Antigenbeta CateninColorectal NeoplasmsHedgehog ProteinsHumansImmune Checkpoint InhibitorsImmunotherapy, AdoptiveJanus KinasesMicroRNAsReceptors, NotchRNA, Long NoncodingSignal TransductionSTAT Transcription FactorsStem CellsWnt ProteinsAC133 Antigenbeta CateninHedgehog ProteinsImmune Checkpoint InhibitorsJanus KinasesMicroRNAsReceptors, NotchRNA, Long NoncodingSTAT Transcription FactorsWnt Proteinscancer stem cellscolorectal cancerimmune checkpoint inhibitorsimmunotherapymicrosatellite instabilityorganoidspatient-derived xenograftspersonalized chemotherapystem cell markersstem cell signaling pathwaystargeted therapies

Identifiers

PMID33565332
PMCPMC8190705

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.